DNLI analyst estimates
Denali Therapeutics (DNLI) analyst ratings, the average price target and its range, and every firm's latest call.
DNLI analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 7, 2026 | Robert W. Baird | Denali Therapeutics price target raised to $34 from $31 at Baird | $34.00 |
| Aug 7, 2026 | UBS | Denali Therapeutics price target raised to $34 from $25 at UBS | $34.00 |
| Jul 23, 2026 | Morgan Stanley | Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley | $36.00 |
| Jul 13, 2026 | Wedbush | Denali Therapeutics price target raised to $26 from $20 at Wedbush | $26.00 |
| Jun 22, 2026 | Stifel Nicolaus | Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) | $41.00 |
| May 22, 2026 | Deutsche Bank | Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank | $31.00 |
| May 22, 2026 | Morgan Stanley | Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley | $35.00 |
| May 8, 2026 | Wedbush | Denali Therapeutics price target lowered to $23 from $25 at Wedbush | $23.00 |
| Mar 26, 2026 | Deutsche Bank | Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank | $35.00 |
| Mar 2, 2026 | Jefferies | Jefferies Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) | $40.00 |
| Jan 8, 2026 | Morgan Stanley | Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley | $40.00 |
| Jan 7, 2026 | UBS | UBS Assumes Denali Therapeutics Inc. (DNLI) at Buy | $25.00 |
| Dec 11, 2025 | Wedbush | Denali Therapeutics price target lowered to $30 from $31 at Wedbush | $30.00 |
| Dec 5, 2025 | Wedbush | Denali Therapeutics price target raised to $31 from $30 at Wedbush | $31.00 |
| Nov 17, 2025 | Stifel Nicolaus | Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) | $37.00 |
- 13 firms rate DNLI: 12 buy, 1 hold, 0 sell.
- The average price target is $33.67 from 6 analysts, from $26.00 to $41.00.
Updated 2026-11-02 23:58 UTC